Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery

Summary

This is a single-center, single-arm phase I study to determine the safety and preliminary efficacy of autologous dendritic cells (DCs) loaded with multiple tumor neoantigen peptides administered as a cancer-treatment vaccine to treat adult postoperative patients with newly-diagnosed glioblastoma, in combination with the standard-of-care Temozolomide (TMZ) chemotherapy.

Timeline

Start

2021-07-30

Primary completion

2024-04-30

Completion

2025-10-31

Publications

• Zhang Y, Chi X, Liu K, Ma Y, Zhang S, Ma X, Sun S, Zhang Y, Zhang K, Huang N, Cheng X, Ji N. Personalized neoantigen-pulsed autologous dendritic cells in newly-diagnosed glioblastoma: a phase Ib trial. Nat Commun. 2026 Jul 4. doi: 10.1038/s41467-026-75066-w. Online ahead of print.

Drugs

Indications